Hints and tips:
Related Special Reports
...At the mid-level, a cashmere style in a muted shade from Sheep Inc, John Smedley or — my favourite — Begg x Co will quickly become a staple of your wardrobe....
...But in May, the FTC sued to block the deal, arguing that “rampant consolidation” in the pharmaceuticals industry is pushing up drug prices....
...But the reality of the Amgen settlement may be somewhat more complex than the Wall Street summation....
...“Issuers often will have financing needs beyond the M&A financing, where they may want to continue to have that debt outstanding if, for whatever reason, the merger or acquisition doesn’t go ahead,” Mead...
...Under the proposed reforms the minimum cut from a drug’s list price will be 25 per cent, although the government may be able to secure much steeper discounts for some drugs....
...The antitrust challenge may force big pharma groups to rethink “pure play” business models. The Lex team is interested in hearing more from readers. Is the FTC right to challenge pharma deals?...
...The Federal Trade Commission’s decision on Tuesday to file a lawsuit to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics was unexpected as most of the people involved didn’t think there was an...
...Between May and July, it felt like economic growth just kept surprising to the upside and stocks, particularly economically sensitive ones, lapped it up....
...Last week, a verdict was passed down in the case of Walkers Snack Foods Ltd v Commissioners for His Majesty’s Revenue and Customs, with first-tier tribunal judges Anne Fairpo and Sonia Gable ruling against...
...Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals...
...At an investor event, the company touted the potential to claim $10bn in annual sales by 2030 — with analysts noting that a once-a-day pill may gain a competitive advantage over weekly or monthly injections...
...UK regulators may now be incentivised to take what they can get given that Brussels cleared the deal in May....
...DD readers may remember Prateek Gupta, the Dubai-based businessman at the centre of the scandal....
...Having been legally shielded until now, the drug this year faces competition from nine “biosimilars” such as Amgen’s Amjevita....
...I think a lot of people were anticipating a V-shaped recovery . . . People are now waking up the realisation that volatility is going to be normal going forward.”...
...Email me your thoughts at sid.v@ft.com. Latest news Amy Kazmin in Rome has a fascinating piece on why Giorgia Meloni is pushing back on Italy’s shift to digital payments....
...Pfizer in May agreed a $11.6bn deal to buy US biotech Biohaven Pharmaceuticals, which is developing migraine treatments....
...days after Roe v....
.... ©2023 Nikkei Inc. All rights reserved....
...“This may not be the right time for the government to go to the market to raise money, as there is so much vulnerability in stock markets,” said V Upadhyay, adjunct professor of economics at the Indian Institute...
...Tech tools — VanMoof X3 e-bike Peloton may be having its problems, but those making on-the-road e-bikes to improve your fitness are riding high in the saddle....
...A broader problem is Apple may not want to do anything that might actually distract people from their phones....
...But glasses and cars are two very big projects that may be its next big thing, he says, or maybe not....
...Players of Fortnite, developed by Epic, were able to purchase an in-game currency known as “V-bucks” online, but these credits would not show up when playing on the iPhone....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
International Edition